The market research report for Non-Opioid Pain Treatment has been meticulously curated, drawing from a systematic gathering and analysis of data specific to the industry. Its aim is to illuminate crucial facts and statistics for enterprises, delivering a thorough examination of the market and its integral components. These encompass various aspects such as market drivers, limitations, segmentation, prospects, hurdles, revenue insights, and competitive evaluations. This invaluable resource equips companies with the necessary information to make well-founded decisions as they navigate their niche market landscape.

Our exceptional team, comprised of analysts, experts, statisticians, forecasters, and economists, devoted rigorous efforts to craft this comprehensive and advanced report on the Non-Opioid Pain Treatment market. It stands as an indispensable instrument for maintaining a competitive advantage. The report dives into market segmentation, delineating potential customer groups based on diverse attributes including product application, deployment models, end-user profiles, and geographical regions.

Moreover, the Non-Opioid Pain Treatment report presents insights into prominent players, significant collaborations, mergers, acquisitions, and emerging trends in innovation and business strategies. It consolidates precise and reliable market research data, providing businesses with a clear roadmap for informed decision-making and strategic planning.

Data Bridge Market Research analyses that the non-opioid pain treatment market which was USD 622.65 million in 2021, would rocket up to USD 807.32 million by 2029, and is expected to undergo a CAGR of 3.30% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Get a Sample Research Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-non-opioid-pain-treatment-market

Pain management is an essential part of medical treatment. Migraine, lower back pain, osteoarthritis, fibromyalgia, localised musculoskeletal pain, and localised neuropathic pain are all examples of chronic pain syndromes. While opioids may be acceptable for acute or chronic pain related to palliative or end-of-life care, as well as current cancer therapy, there are also non-opioid pain management choices. Non-opioid pain treatment is an option for mild to moderate pain. Non-opioid pain relief is available without a prescription and as over-the-counter medications.

Key Growth Drivers:

  • Increasing prevalence of osteoarthritis

The rising global prevalence of osteoarthritis, fueled by the ageing population, joint injuries, obesity, repeated stress on the joint, genetics, metabolic illnesses, and bone abnormalities, is expected to fuel demand for non-opioid pain treatment patches. It is the most prevalent type of arthritis, and it most commonly affects the knees, hips, and hands. According to the Osteoarthritis Action Alliance (OAAA), approximately 54.4 million adults in the United States have some type of arthritis, with that number anticipated to rise to 78 million by 2040. Osteoarthritis affects roughly 32.5 million persons in the United States. This tendency is expected to continue in many regions of the world in the future years, propelling the market forward.

  • Increasing cases of cancer

Breast, bowel, colorectal, and lung cancer cases are predicted to increase in the next years, propelling the industry forward. The market is expected to benefit from increased awareness among governments in various countries about the availability of novel non-opioid heat patches for the treatment of cancer-related pain. According to the World Health Organization (WHO), cancer will kill approximately 10 million people worldwide in 2020. Breast cancer claimed over 6,85, 000 lives in the same year, while liver cancer claimed 8,30,000 lives and lung cancer claimed 1.80 million lives. This showcases that the prevalence of cancer is set to surge at a fast pace in the near future, which would drive the market.

The report outlines the involvement of key players, including:

Eli Lilly and company (U.S.), Regeneron Pharmaceuticals Inc. (U.S.), Centrexion Therapeutics Corp. (U.S), Acorda Therapeutics (U.S.), Biogen (U.S.), VM Biotech (U.S.), Novartis AG (Switzerland), Alder Biopharmaceuticals (U.S.), Sanofi (France), Pfizer Inc. (U.S.), GSK plc. (U.K.), Hisamitsu Pharmaceutical Co., Inc. (Japan), Clarion (U.S), Endo Pharmaceuticals (Ireland), TEH SENG PHARMACEUTICAL MFG. CO., LTD. (Taiwan), Veridian Healthcare (U.S.), Sorrento Therapeutics, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Teikoku Seiyaku Co. Ltd. (Japan)

Key Market Segmentation

Products (Medical Cannabis, Menthol- Containing, Omega 3 Fatty Acid Containing, Botulinum Toxins, Capsaicin Derived), Therapeutic Applications (Orthopaedic and Musculoskeletal Pain, Neuropathic Pain, Cancer Pain, Other Pain), Drug Type (Acetaminophen, Non-steroidal Anti-inflammatory Drugs, Corticosteroids, Anticonvulsants, Serotoninnorepinephrine Reuptake Inhibitor Antidepressants), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies)

The Non-Opioid Pain Treatment market report includes the following countries in different regions:

The regions mentioned above encompass a comprehensive coverage of key markets, offering a global perspective on the market landscape. Here's an overview of the regions and the countries they include:

  1. North America: United States, Canada, and Mexico.
  2. Europe: Germany, France, United Kingdom, Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, and other European countries.
  3. Asia-Pacific (APAC): China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, and other Asia-Pacific countries.
  4. Middle East and Africa (MEA): Saudi Arabia, United Arab Emirates (U.A.E), South Africa, Egypt, Israel, and other countries in the Middle East and Africa region.
  5. South America: Brazil, Argentina, and other countries in South America.

North America dominates the non- opioid pain treatment market due to growing clinical trials and increasing funding by the government.

Asia-Pacific is expected to show significant growth, due to changing economic demographic which improves the drug affordability, rising health insurance and low cost of production and R&D boosts efficiency of pharmaceutical companies in the emerging countries such as India.

 

Know More about This Premium Research Report @ https://www.databridgemarketresearch.com/reports/global-non-opioid-pain-treatment-market

Browse More Reports:

https://www.databridgemarketresearch.com/reports/global-mycophenolate-market

https://www.databridgemarketresearch.com/reports/global-variant-creutzfeldt-jakob-disease-treatment-market

https://www.databridgemarketresearch.com/reports/global-anti-money-laundering-market

https://www.databridgemarketresearch.com/reports/europe-anti-money-laundering-market

https://www.databridgemarketresearch.com/reports/asia-pacific-anti-money-laundering-market

About Data Bridge Market Research, Private Ltd

Data Bridge Market Research is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe.

Contact Us

US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email – corporatesales@databridgemarketresearch.com